| Malignant neoplasm of breast
Arimidex vs Ibrance
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Arimidex vs Ibrance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIbrance has a higher rate of injection site reactions vs Arimidex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ibrance but not Arimidex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Arimidex
Ibrance
At A Glance
Oral
Daily
Aromatase inhibitor
Oral
Once daily (21 of 28 days)
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Locally advanced breast cancer
- Carcinoma breast stage IV
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast 1 mg tablet orally once daily; adjuvant treatment duration in the ATAC trial was 5 years.
Locally advanced breast cancer, Carcinoma breast stage IV 1 mg tablet orally once daily; continue until tumor progression.
Malignant neoplasm of breast 125 mg orally once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle; taken with food. Dose may be reduced to 100 mg or 75 mg for adverse reactions; patients with severe hepatic impairment (Child-Pugh C) start at 75 mg once daily.
Contraindications
- Hypersensitivity to anastrozole or any excipient (including anaphylaxis, angioedema, and urticaria)
—
Adverse Reactions
Most common (>=10%) Hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, lymphedema
Serious Skin lesions, ulcers, or blisters; severe allergic reactions with swelling of face, lips, tongue, and/or throat; liver function abnormalities including hepatitis
Postmarketing Hepatobiliary events (increases in alkaline phosphatase, ALT, AST, gamma-GT, and bilirubin; hepatitis), erythema multiforme, Stevens-Johnson syndrome, angioedema, urticaria, anaphylaxis, myalgia, hypercalcemia, tendon disorders including tendon rupture and tendonitis
Most common (>=10%) Neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeusia
Serious Neutropenia, leukopenia, infections, anemia
Postmarketing Interstitial lung disease (ILD)/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome (PPES)
Pharmacology
Anastrozole is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme, significantly lowering serum estradiol concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone formation.
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6; it blocks progression of ER-positive breast cancer cells from G1 into S phase of the cell cycle, and in combination with antiestrogens decreases Rb protein phosphorylation, reduces E2F expression, and increases growth arrest.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Arimidex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Arimidex
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Arimidex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ArimidexView full Arimidex profile
IbranceView full Ibrance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.